This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Other restrictive cardiomyopathy기타 제한성 심근병증

ICD-10 codeI42.5
Special Copayment Reduction codeV289
Synonyms / related termsRestrictive cardiomyopathy (RCM), amyloid cardiomyopathy, sarcoid cardiomyopathy, idiopathic restrictive cardiomyopathy, ATTR cardiomyopathy
ClassificationSevere intractable disease (Special Copayment Reduction registration criteria: 5 years)

History

Restrictive cardiomyopathy (RCM) is a myocardial disease characterized by impaired ventricular filling due to increased myocardial stiffness, in which systolic function is relatively preserved but diastolic function is severely reduced. After Brigden proposed a classification of cardiomyopathies in 1957, RCM was included as the third major form of cardiomyopathy in the 1980 WHO/ISFC classification.

Amyloidosis has received the most attention as a cause of RCM. Since the 1990s, fluorescence immunohistochemistry, and since the 2000s, nuclear medicine testing (99mTc-DPD/pyrophosphate scintigraphy), have made it possible to diagnose transthyretin (ATTR) amyloidosis. The introduction of therapies for hereditary ATTR (ATTRv), tafamidis (FDA-approved in 2019) and iRNA therapeutics (vutrisiran, patisiran), has increased diagnostic activity.

I42.5 (other restrictive cardiomyopathy) includes other forms of RCM with primary or secondary causes that are not classified elsewhere. In Korea it is eligible for Special Copayment Reduction (V289); diagnosis is difficult and prognosis is poor, so specialist management is important.

Causes

RCM is divided into primary and secondary types. Primary RCM is of unknown cause (idiopathic) or due to genetic causes; secondary RCM arises from cardiac involvement in systemic disease.

Primary RCM: idiopathic RCM (no gene variant identified); hereditary RCM (variants in sarcomere/cytoskeletal proteins such as TNNI3, TNNT2, MYH7, DES [desmin], FLNC, and MYPN). Idiopathic RCM is an important cause of heart failure and pulmonary hypertension of unknown cause in children.

Secondary RCM (infiltrative/storage causes): ① amyloidosis (ATTR [ATTRv hereditary, ATTRwt senile], AL light-chain amyloidosis); ② sarcoidosis (cardiac sarcoidosis); ③ hemochromatosis (HFE gene variants); ④ glycogen storage disease (Pompe, Danon); ⑤ Fabry disease (GLA variants; mainly an HCM phenotype but may resemble RCM); ⑥ hypereosinophilic syndrome (endomyocardial fibrosis); ⑦ radiation-induced cardiac fibrosis; ⑧ systemic sclerosis; ⑨ carcinoid (right-sided fibrosis).

Genetics

In primary RCM, genetic testing is very important for clinical diagnosis. TNNI3 (cardiac troponin I) variants are the best-known cause of primary RCM, show autosomal dominant inheritance, and may be accompanied by atrial fibrillation and conduction disturbances.

DES (desmin) variants cause "desminopathy," a combination of skeletal myopathy (limb-girdle, distal myopathy) and cardiac involvement (ventricular arrhythmia, conduction disturbance, RCM or DCM phenotype). Clinical differentiation from cardiac sarcoidosis and amyloidosis is particularly necessary.

FLNC (filamin C) variants present with a DCM or RCM phenotype and carry a high risk of ventricular arrhythmia. MYH7 variants mainly present with an HCM phenotype, but in some cases appear with an RCM phenotype. ATTRv (hereditary transthyretin amyloidosis): TTR gene variants (Val122Ile, common in African Americans; Val30Met, in Europeans and Asians) cause ATTR cardiomyopathy, and early tafamidis treatment can slow the course. A genetic panel test (cardiomyopathy gene panel) is recommended.

Epidemiology

RCM is the rarest form of cardiomyopathy, and accurate incidence data are limited. The prevalence in the general population is estimated at about 1-2 per 100,000 and may be higher if amyloidosis is included as a cause. ATTR cardiomyopathy was previously regarded as a rare disease, but advances in diagnostic technology are revealing that the actual prevalence of senile ATTRwt is considerably high (10-15% of elderly heart failure patients).

Idiopathic RCM is relatively important in children, accounting for 2-5% of all pediatric cardiomyopathies in pediatric cardiomyopathy registry data. The 5-year survival rate in pediatric RCM is about 50-70%, and mortality while awaiting transplantation is high.

Epidemiologic data in Korea are very limited. Among secondary causes, cardiac sarcoidosis is known to involve the heart more frequently in Asians (especially Japanese and Koreans) than in Westerners. Diagnosis of amyloidosis-related RCM is increasing rapidly in Korea. After registration for Special Copayment Reduction (V289), renewal is required every 5 years.

Pathophysiology

The core pathophysiology of RCM is impaired diastolic filling due to decreased ventricular compliance. When ventricular stiffness increases, diastolic pressure rises sharply even with the same volume increase (high filling pressure), and as a result pulmonary and systemic congestion occur even without a decrease in cardiac output.

In infiltrative causes: when amyloid fibrils are deposited in the myocardial interstitium, myocardial elasticity decreases and cardiomyocyte toxicity is added (especially direct cytotoxicity of AL amyloid). In sarcoidosis, granuloma deposition causes conduction disturbance, myocardial inflammation, and fibrosis. In hemochromatosis, iron deposition causes oxidative damage to cardiomyocytes and fibrosis.

In hereditary RCM: abnormal calcium sensitivity (Ca2+ oversensitivity) due to TNNI3 variants causes delayed relaxation and increased ventricular stiffness. Disruption of the intermediate filament network due to desmin variants leads to abnormal cardiomyocyte mechanical signaling and structural stability. In all mechanisms, atrial enlargement and pulmonary hypertension commonly progress and develop into right heart failure.

Symptoms

The main symptoms of RCM are heart failure symptoms due to diastolic dysfunction. Left heart failure: exertional dyspnea (sharp rise in ventricular filling pressure during exercise), orthopnea, paroxysmal nocturnal dyspnea, pulmonary edema. It begins as mild exercise intolerance and worsens gradually.

Right heart failure symptoms (with progression): leg edema, abdominal distension (ascites), hepatomegaly, jugular venous distension. In cases of marked weight gain, cardiac ascites or generalized edema is prominent. Syncope and dizziness: caused by conduction disturbance (AV block, bundle branch block) or atrial fibrillation. Conduction disturbance and ventricular arrhythmia are especially prominent in cardiac sarcoidosis and desminopathy.

Thromboembolism: atrial enlargement and intra-atrial thrombus formation due to atrial fibrillation can cause stroke and peripheral embolism. In amyloidosis-related RCM, hypotension, dizziness, concomitant multiple myeloma (AL type), carpal tunnel syndrome (a preceding symptom of ATTRv), peripheral neuropathy, and lower-limb autonomic dysfunction also appear.

Signs

On physical examination, jugular venous distension (JVD), Kussmaul sign (paradoxical rise in JVP on inspiration; a key point for differentiation from constrictive pericarditis), pitting edema of the legs, ascites, and hepatomegaly are observed as signs of right heart failure. Systolic function is preserved, so heart size is often normal or shows only atrial enlargement.

Auscultatory findings: S3 or S4 gallop (in severe diastolic dysfunction), tricuspid and mitral regurgitation murmurs, accentuated P2 due to pulmonary hypertension, fixed split S2. The pulse is normal or weak (decreased stroke volume), and an irregular pulse is observed in atrial fibrillation.

Findings in amyloidosis: periorbital purpura (AL type), tongue enlargement (macroglossia; AL type), carpal tunnel syndrome, bilateral renal enlargement, proteinuria (AL type). On CMR, extensive LGE (especially a subendocardial or transmural pattern unrelated to coronary artery distribution) and increased T1 mapping are characteristic findings of amyloid deposition.

Screening

Electrocardiogram (ECG): in RCM, low QRS voltage (characteristic of amyloidosis), pseudoinfarction pattern, atrial fibrillation, bundle branch block, and AV conduction disturbance may be observed. In amyloidosis, a discrepancy between decreased QRS voltage and echocardiographic ventricular wall thickening is a diagnostic clue.

Echocardiography: normal ventricular size or atrial enlargement, LV wall thickness (thickened or normal), normal or mildly decreased LVEF, severe diastolic dysfunction (E/e' > 15, TR velocity > 2.8 m/s suggesting pulmonary hypertension), myocardial sparkling (granular sparkling; amyloidosis), and pericardial effusion suggest RCM.

Biomarkers: elevated BNP/NT-proBNP, serum protein electrophoresis (SPEP)/immunofixation electrophoresis (IFEP; screening for AL amyloid), free light chains, serum ferritin/transferrin saturation (hemochromatosis), ACE level (sarcoidosis). 99mTc-DPD/pyrophosphate cardiac scan: high specificity for diagnosing ATTRwt or ATTRv amyloidosis.

Diagnosis

RCM is diagnosed by integrating clinical findings, echocardiography, CMR, and tissue biopsy. Key diagnostic criteria: ① normal or decreased ventricular volume, ② normal or mildly decreased LVEF, ③ severe diastolic dysfunction (restrictive filling pattern; E/A > 2, deceleration time < 150 ms, E/e' > 15), ④ atrial enlargement, ⑤ symptoms of congestive heart failure, ⑥ structural or functional abnormalities not explained by ischemia, hypertension, or valvular disease.

Differentiation from constrictive pericarditis is clinically very important. CMR (pericardial thickness, pericardial LGE), cardiac catheterization (ventricular pressure concordance testing), and assessment of respiratory variation are used for differentiation. Endomyocardial biopsy (EMB): used to identify amyloid (Congo red stain positive, apple-green birefringence under polarized light), sarcoidosis (non-caseating granuloma), giant cell myocarditis, and hemochromatosis (iron stain).

Genetic testing: TTR gene test (ATTRv amyloidosis), cardiomyopathy gene panel (causative genes of primary RCM). For registration for Special Copayment Reduction (V289), submit a cardiologist's diagnosis certificate, echocardiography results (including diastolic function indices), EMB results if necessary, and CMR results.

Treatment

Treatment of RCM consists of two pillars: cause-specific treatment of the underlying disease and management of heart failure symptoms. Because diastolic dysfunction is the main mechanism, the effect of standard HFrEF drugs (ACEi, beta-blockers, MRA) is limited, and an approach focused on improving diastolic function is needed.

Cause-specific treatment: ATTR amyloidosis: tafamidis (20-80 mg QD; the ATTR-ACT study confirmed reductions in mortality and cardiovascular hospitalization), "Acona" amyloid inhibitor (vutrisiran; iRNA). AL amyloidosis: hematology-oncology consultation, autologous stem cell transplantation (ASCT), chemotherapy combined with daratumumab. Sarcoidosis: steroids (corticosteroid; when accompanied by conduction disturbance and ventricular arrhythmia), methotrexate, azathioprine combination. Hemochromatosis: regular phlebotomy, chelation therapy (deferasirox, deferoxamine).

Symptomatic treatment: control congestion with diuretics (loop diuretics, spironolactone) - caution, as excessive diuresis reduces cardiac output. Atrial fibrillation: rhythm control or rate control, anticoagulation. Artificial pacemaker when conduction disturbance is present. ICD implantation in cases at high risk of ventricular arrhythmia (sarcoidosis, desminopathy). In advanced heart failure, heart transplantation is the final treatment option, but the risk of recurrence after transplantation must be considered in amyloidosis.

Prognosis

RCM is one of the forms of cardiomyopathy with the poorest prognosis. The 5-year survival rate of idiopathic RCM is about 30-50%, and is worse in children. AL amyloid cardiomyopathy (cardiac involvement) had a very poor prognosis, with a median survival of less than 6 months after diagnosis without treatment, but survival has been extended by recent chemotherapy and ASCT.

ATTR cardiomyopathy (ATTRwt and ATTRv) progresses relatively more slowly than AL, and 3-year survival has improved significantly with tafamidis treatment. Cardiac sarcoidosis has a poor prognosis when accompanied by complete atrioventricular block, ventricular arrhythmia, or heart failure, and functional recovery is possible in some cases with steroid treatment.

Predictors of poor prognosis: markedly elevated NT-proBNP, severe diastolic dysfunction (E/A > 2, deceleration time < 150 ms), pulmonary arterial hypertension, hyponatremia, atrial fibrillation, elevated creatinine, extensive LGE on CMR. The 5-year survival rate after heart transplantation is about 70%, but recurrence after transplantation is a problem in infiltrative causes (AL, ATTR). Prognosis continues to improve with advances in treatment of the underlying disease.

Prevention

Primary prevention of primary hereditary RCM is not possible. When a genetic diagnosis is made, screening of first-degree relatives (echocardiography, ECG, genetic testing) is important for early diagnosis and prevention of secondary complications.

Prevention of secondary RCM: early genetic diagnosis of ATTRv amyloidosis and early administration of tafamidis can delay cardiac involvement. Early diagnosis of hemochromatosis (HFE gene testing, serum ferritin/transferrin saturation) and regular phlebotomy prevent cardiac involvement. In hypereosinophilic syndrome, treatment of the cause (imatinib, steroids, mepolizumab) suppresses progression of endomyocardial fibrosis.

Early recognition of atrial fibrillation and initiation of anticoagulation, pacemaker implantation for conduction disturbance, and ICD implantation in patients at risk of ventricular arrhythmia are key to preventing life-threatening complications. Dietary sodium restriction, regulated fluid intake, and infection prevention (influenza/pneumococcal vaccines) minimize worsening of heart failure. At the 5-year renewal of Special Copayment Reduction, the latest diagnostic results and the course of treatment of the underlying disease are entered on the specialist's confirmation.

References

  1. Ammash NM, Seward JB, Bailey KR, Edwards WD, Tajik AJ. Clinical profile and outcome of idiopathic restrictive cardiomyopathy. Circulation. 2000;101(21):2490-2496. PMID: 10831525
  2. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007-1016. PMID: 30145929
  3. Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light-Chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol. 2016;68(12):1323-1341. PMID: 27634130
  4. Rapezzi C, Arbustini E, Caforio AL, et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(19):1448-1458. PMID: 23386398
  5. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404-2412. PMID: 27143678
  6. Muchtar E, Blauwet LA, Gertz MA. Restrictive cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121(7):819-837. PMID: 28935820
  7. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. PMID: 34447992
  8. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015;36(41):2793-2867. PMID: 26320108
  9. Seward JB, Casaclang-Verzosa G. Infiltrative cardiovascular diseases: cardiomyopathies that look alike. J Am Coll Cardiol. 2010;55(17):1769-1779. PMID: 20413021
  10. Kim TH, Kim IS, Oh SM, et al. Clinical characteristics and outcomes of restrictive cardiomyopathy in Korean patients. Korean Circ J. 2020;50(8):703-712. DOI: 10.4070/kcj.2019.0397